Carl recently completed its IPO in July 2025 but is experiencing substantially higher cash burn despite growing gross profit, raising concerns about operational efficiency during its early commercial phase.
The company's operating cash flow deteriorated meaningfully while gross profit grew 25%, suggesting operational scaling challenges as this medical device company ramps commercialization of its spinal implant technology. The IPO provides a strong cash position of $115.4 million as of September 30, but the accelerating burn rate warrants close monitoring of runway and path to profitability.
Carl shows mixed financial trends in its post-IPO quarter, with gross profit growing solidly by 25% to $12.4 million while R&D expenses increased modestly. However, operating cash flow burned substantially more cash, deteriorating from -$8.2 million to -$13.0 million, indicating operational inefficiencies despite revenue growth. The company maintains a solid liquidity position with current liabilities declining 32% and cash reserves of $115.4 million, though cash decreased from prior quarter levels as the business scales operations.
Operating cash flow fell 59.5% — earnings quality concerns; investigate working capital changes and non-cash items.
Current liabilities reduced — improved short-term financial position and working capital health.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
R&D investment increased 16.5% — signals commitment to future product development, though near-term margin impact.
Liabilities reduced 15.1% — deleveraging improves balance sheet strength and financial flexibility.
Cash decreased 14.9% — monitor burn rate and upcoming capital needs.
Inventory built 11.8% — monitor whether demand supports this build or if write-downs may follow.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →